May 6 (Reuters) - Australian biotech firm CSL Ltd (CSL) said on Wednesday it will start local development of an immunoglobulin product to treat serious cases of COVID-19, the disease caused by the novel coronavirus.
The company's unit CSL Behring will develop the immunoglobulin product at its Melbourne-based Broadmeadows facility using antibodies from plasma collected from people who have recovered from COVID-19, CSL said in a statement on its website.
CSL expects around 800 plasma donations will be needed to produce enough immunoglobulin to treat around 50-100 seriously ill people under the clinical trial, it said.
News: CSL Australia's CSL to start work on immunoglobulin product to treat COVID-19
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$288.80 |
Change
-0.300(0.10%) |
Mkt cap ! $139.5B | |||
| Open | High | Low | Value | Volume |
| $288.06 | $290.40 | $287.86 | $189.1M | 654.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 500 | $288.75 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $288.81 | 1380 | 2 |
View Market Depth
| Last trade - 16.10pm 17/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$288.01 |
Change
-0.300 ( 0.37 %) |
||||
| Open | High | Low | Volume | ||
| $288.40 | $290.39 | $287.66 | 103444 | ||
| Last updated 15.59pm 17/06/2024 ? | |||||
| CSL (ASX) Chart |
